Peer-reviewed veterinary case report
Blood test for PD-1 and PD-L1 to detect tumors in dogs
By Song, Doo-Won et al.·Published in Journal of veterinary science·2021·College of Veterinary Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors.
- Species:
- dog
Plain-English summary
A study found that dogs with tumors had higher levels of certain proteins (PD-1 and PD-L1) in their blood compared to healthy dogs. These proteins help tumors evade the immune system, and their increased levels could be useful for diagnosing tumors in dogs. Specifically, dogs with malignant epithelial tumors and lymphomas showed significant differences in these protein levels compared to healthy dogs. This suggests that measuring PD-1 and PD-L1 could help veterinarians identify tumors more effectively in dogs.
People also search for: dog tumor diagnosis · elevated PD-1 PD-L1 in dogs · lymphoma symptoms in dogs · cancer blood test for dogs
Abstract
BACKGROUND: Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have important roles in tumor evasion of the immune system. OBJECTIVES: This study aimed to assess the diagnostic utility of circulating PD-1 and PD-L1 levels in healthy dogs and dogs with tumors. METHODS: Circulating PD-1 and PD-L1 levels in the serum of 71 dogs with tumors were compared with those of 52 healthy dogs by performing enzyme-linked immunosorbent assay (ELISA). RESULTS: The ELISA results revealed higher circulating PD-1 and PD-L1 levels in dogs with tumors (2.9 [2.2-3.7] ng/mL; median [IQR] and 2.4 [1.4-4.4] ng/mL, respectively) than in healthy dogs (2.4 [1.9-3.0] ng/mL;= 0.012 and 1.4 [0.9-2.1] ng/mL;< 0.001, respectively). Especially, there was a significant difference in circulating PD-1 levels between healthy dogs and dogs with malignant epithelial tumors (2.4 [1.9-3.0] ng/mL and 3.1 [2.6-4.4] ng/mL, respectively;< 0.01). In addition, there was a significant difference in circulating PD-L1 levels between healthy dogs and dogs with lymphomas (1.4 [0.9-2.1] ng/mL and 2.7 [1.6-5.8] ng/mL, respectively;< 0.001). CONCLUSION: This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34553519/